Subscribe to RSS
DOI: 10.1055/s-0038-1657153
Inhibition of Thrombin-Neutralizing Activity of Antithrombin III by Steroid Hormones
Publication History
Received 24 September 1981
Accepted 02 March 1982
Publication Date:
13 July 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/198202/lookinside/thumbnails/10-1055-s-0038-1657153-1.jpg)
Summary
Estrogens in high doses have been shown to inhibit, in vitro, the thrombin-neutralizing action of antithrombin III (AT III). In this study we investigate the effect of estrogens on AT III in greater detail. To increase the sensitivity of measurement of AT III activity in the absence of heparin, we have developed an assay system utilizing human platelets, AT III and thrombin. The two proteins derived from human plasma were prepared in high purity. Platelet aggregation was induced by approximately 0.02 NIH U of thrombin. AT III was added in amounts that suppressed 95% of the aggregation-inducing effect of thrombin. Estrogens blocked the thrombin-neutralizing effect of AT III in dose-dependent manner. This effect was shown to be specific for AT III. Neither aggregability of platelets nor aggregating effect of thrombin were affected by the steroid hormone. Evidence for binding of estrogen to AT III was obtained from changes in intrinsic fluorescence of AT III. Activity of AT III was also reduced in increasing order of effectiveness by cholesterol, cortisone, testosterone and progesterone. Our studies suggest a direct effect of estrogens and other steroids on AT III, altering its specific neutralization of thrombin.
-
References
- 1 Poller L, Thomson JM, Tabiowo A, Priest CH. Progesterone, oral contraceptives and blood coagulation. Br Med J 1969; 1: 554-556
- 2 Poller L, Thomson JM. Sequential oral contraception and clotting factors. Br Med J 1969; 2: 822-823
- 3 Poller L, Thomson JM, Thomas W. Oestrogen/progesteron oral contraception and blood clotting; a long-term follow-up. Br Med J 1971; 4: 648-650
- 4 Ygge J, Brody S, Korsan-Bengtsen K, Nilsson L. Changes in blood coagulation and fibrinolysis in women receiving oral contraceptives. Am J Obstet Gynecol 1969; 104: 87-98
- 5 McGrath KM, Castaldi PA. Cyclical changes in coagulation factors associated with the use of progestational agents. Haemostasis 1975; 4: 73-80
- 6 Hougie C, Rutherford RM, Banks AL. Effect of a progestin-estrogen oral contraceptive on blood clotting factors. Metabolism 1965; 14: 411-417
- 7 von Kaulla E, von Kaulla KN. Oral contraceptives and low antithrombin III activity. Lancet 1970; 1: 36
- 8 Fagerhol MK, Abildgaard U. Immunological studies on human antithrombin III. Influence of age, sex and use of oral contraceptives on serum concentrations. Scand J Hematol 1970; 7: 10-17
- 9 Howie PW, Mallison AC, Prentice CR, Horne CHW, McNichol GP. Effect of combined oestrogen-progestrogen oral contraceptives, oestrogen, and pregestrogen on antiplasmin and antithrombin activity. Lancet 1970; 2: 1329-1332
- 10 von Kaulla E, Droegemueller W, Aoki N, von Kaulla KN. Antithrombin III depression and thrombin generation acceleration in women taking oral contraceptives. Am J Obstet Gynecol 1971; 109: 868-873
- 11 Zuck TF, Bergin JJ, Raymond JM, Dwyre WR. Implications of depressed antithrombin III activity associated with oral contraceptives. Surgery Gynec Obstet 1971; 133: 609-612
- 12 Conard J, Samama M, Solomon Y. Antithrombin III and the estrogen content of combined estro-progestrogen contraceptives. Lancet 1972; 2: 1148
- 13 Gitel SA, Wessler S. Plasma antithrombin III. A quantitative assay of biological activity. Thromb Res 1975; 7: 5-16
- 14 Hedlin AM. The effect of oral contraceptive estrogen on blood coagulation and fibrinolysis. Thrombos Diathes Haemorrh 1975; 33: 370-378
- 15 Sagar S, Stamatakis JD, Thomas DP, Kakkar VV. Oral contraceptives, antithrombin III activity and postoperative deep-vein thrombosis. Lancet 1976; 1: 509-511
- 16 Ambrus JL, Ambrus C, Lillie MA, Brown BJ, Hanson FW, Niswander K, Mitul M, Jung OA, Bartfay-Szabo A. Effect of various estrogen treatment schedules on antithrombin III levels. Res Commun Chem Pathol Pharmacol 1976; 14: 543-549
- 17 Ball AP, McKee PA. Fibrin formation and dissolution in women receiving oral contraceptive drugs. J Lab Clin Med 1977; 89: 751-762
- 18 Howie PW, Prentice CR, McNichol GP. A method of antithrombin estimation using plasma defibrinations with ancrod. Br J Haematol 1973; 25: 101-110
- 19 Nagasawa H, Hotta Y, Takara N, Fujimaki M, Fukutake K. Inhibitory effects of estrogens on antithrombin III. Thrombos Diathes Haemorrh 1975; 34: 345 (Abstract)
- 20 Abildgaard U. Purification of two progressive antithrombins of human plasma. Scand J Clin Lab Invest 1967; 19: 180-195
- 21 Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-6505
- 22 Gerendas M. Thrombin inactivation as an enzymatic process. Thrombos Diathes Haemorrh 1959; 4: 56-70
- 23 Maizel JV. Acrylamide gel electrophoresis of proteins and nucleic acids. In: Habel K, Salzman NP. (eds) Fundamental Techniques in Virology. Vol. 32 New York: London Academic Press; 1969: 334-362
- 24 Miller-Anderson M, Borg H, Anderson LO. Purification of antithrombin III by affinity chromatography. Thromb Res 1974; 5: 439-452
- 25 Lundblad RL. A rapid method for the purification bovine thrombin. Biochemistry 1971; 10: 2501-2505
- 26 Odegard OR, Lie M, Abildgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb Res 1975; 6: 287-294
- 27 Fenton Jr JW, Fasco MJ, Stackrow AB, Aronsen DL, Young AM, Finlayson JS. Human thrombins: Production, evaluation and properties of alpha-thrombin. J Biol Chem 1977; 252: 3587-3598
- 28 Lowry OH, Rosebrough N, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-275
- 29 Weeke B. Crossed immunoelectrophoresis. Scand J Immunol 1973; 2: 47-56
- 30 Sas G, Pepper DS, Cash JD. Investigations on antithrombin III in normal plasma and serum. Br J Haematol 1975; 30: 265-272
- 31 Kim BK, Baldini MG. Biochemistry, function, and hemostatic effectiveness of frozen human platelets. Proc Soc Exper Biol Med 1974; 145: 830-835
- 32 Brand L, Witholt B. Fluorescence measurement in “pMethods in Enzymology”. 1967; 11: 776-856
- 33 Watanabe K, Chao FC, Tullis JL. Platelet antithrombin: Role of thrombin binding and the release of platelet fibrinogen. Br J Haematol 1977; 35: 123-133
- 34 Mohammed SF, Whitworth C, Chuang HYK, Lundblad RL, Mason RG. Multiple active forms of thrombin. Binding to platelets and effects on platelet function. Proc Natl Acad Sci USA 1976; 73: 1660-1663
- 35 Griffith MJ, Kingdon HS, Lundblad RL. Inhibition of the heparinantithrombin III/thrombin reaction by active site blocked-thrombin. Biochim Biophys Acta 1979; 87: 686-692
- 36 Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246: 355-357
- 37 Pomerantz MW, Owen WG. A catalytic role for heparin. Evidence for a ternary complex of heparin cofactor thrombin and heparin. Biochim Biophys Acta 1978; 535: 66-77
- 38 Griffith MJ. Kinetic analysis of the heparin-enhanced antithrombin III/thrombin reaction. Reaction rate enhancement by heparinthrombin association. J Biol Chem 1979; 254: 12044-12049
- 39 Klein PD, Seegers WH. The nature of plasma antithrombin activity. Blood 1980; 5: 542-752
- 40 Kim BK, Steiner M, Baldini MG. Antithrombin III binds to human platelets. Biochem Biophys Res Commun 1980; 97: 1227-1232